💊Key Details - Upadacitinib
Upadacitinib is a selective Janus kinase (JAK1) inhibitor that reduces inflammation by blocking cytokine signaling involved in immune responses:
☑️Indications: autoimmune conditions such as rheumatoid arthritis, atopic dermatitis, and ulcerative colitis.
☑️Mechanism: by inhibiting JAK-STAT pathways, it decreases production of pro-inflammatory mediators.
☑️Adverse effects: upper respiratory tract infections, fever, thrombosis, and an increased risk of malignancy.
☑️Boxed warning: upadacitinib carries a boxed warning for serious heart-related events, cancer, blood clots, and death.
☑️Interactions: drugs that strongly inhibit CYP 3A4 increase upadacitinib levels.
☑️Brand name: Rinvoq